176 related articles for article (PubMed ID: 38144400)
1. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B.
Azhari H; Frolkis AD; Shaheen AA; Israelson H; Pinto J; Congly SE; Borman MA; Aspinall AA; Stinton LM; Nguyen HH; Swain MG; Burak KW; Lee SS; Sadler MD; Coffin CS
Can Liver J; 2022 Nov; 5(4):453-465. PubMed ID: 38144400
[No Abstract] [Full Text] [Related]
2. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
[TBL] [Abstract][Full Text] [Related]
4. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
6. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
[TBL] [Abstract][Full Text] [Related]
8. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis.
Tseng CH; Chen TH; Wu JL; Lee TY; Borghi JA; Lin JT; Nguyen MH; Hsu YC
JHEP Rep; 2023 Jan; 5(1):100617. PubMed ID: 36466989
[TBL] [Abstract][Full Text] [Related]
9. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
[TBL] [Abstract][Full Text] [Related]
10. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
[TBL] [Abstract][Full Text] [Related]
11. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
Chien RN; Liaw YF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
[TBL] [Abstract][Full Text] [Related]
12. Finite nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B: From an "option" to an "active recommendation".
Liaw YF; Chien RN
Kaohsiung J Med Sci; 2022 Apr; 38(4):295-301. PubMed ID: 35262284
[TBL] [Abstract][Full Text] [Related]
13. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B.
Wong GL; Chan HL; Yuen BW; Tse YK; Luk HW; Yip TC; Hui VW; Liang LY; Lee HW; Lui GC; Wong VW
Liver Int; 2020 Mar; 40(3):549-557. PubMed ID: 31845462
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
Tseng TC; Kao JH
J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
[TBL] [Abstract][Full Text] [Related]
16. Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals.
Liu YC; Jeng WJ; Peng CW; Chien RN; Liaw YF
Aliment Pharmacol Ther; 2024 Mar; 59(6):762-773. PubMed ID: 38234285
[TBL] [Abstract][Full Text] [Related]
17. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
18. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Peng CW; Jeng WJ; Yang HI; Liu YC; Chien RN; Liaw YF
J Gastroenterol Hepatol; 2022 Nov; 37(11):2164-2172. PubMed ID: 35869752
[TBL] [Abstract][Full Text] [Related]
19. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.
Liaw YF
Hepatol Int; 2019 Nov; 13(6):665-673. PubMed ID: 31559604
[TBL] [Abstract][Full Text] [Related]
20. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B.
Leung RH; Hui RW; Mak LY; Mao X; Liu KS; Wong DK; Fung J; Seto WK; Yuen MF
J Hepatol; 2024 Mar; ():. PubMed ID: 38527527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
